Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite Inc.

Division of Abbott Laboratories Inc.
www.biosite.com

Latest From Biosite Inc.

Is Diagnostics the New Biotech...and Will Pharma Embrace It?

The early biotech industry thrived on a combination of hope and hype while diagnostics, which evolved using many of the same tools, was traditionally viewed -- and priced -- almost as a commodity. Now we're seeing the advent of complex, high-value diagnostics. As the techniques underlying tests increase in their biological complexity and the knowledge base of their developers about specific disease areas deepens, is the value proposition becoming more biotech-like?

Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests

The availability of novel assay platforms represents a tipping point for diagnostics' adoption in the markets for translational medicine, esoteric testing, and high-complexity labs. Platform companies may be accustomed to defining their business strategies in terms of maximizing instrument placements but this may not be the optimal path to commercial success for a novel diagnostic test. They need to develop "category-killer" tests--those that combine platform and diagnostic content to offer a compelling clinical value proposition.
Medical Device Business Strategies

Wireless Health: Personalized Medicine Comes to the Device Industry

This is the device industry's wireless wake-up call. With all the speed and acceleration of an advancing information technology industry, forces outside of the medical device industry are driving shifts in medical product markets and business models. Those forces include the consumerization. globalization, systematization, and economies of scale created by IT. Wireless medicine enables connectivity between caregivers and patients, continuous monitoring of patients with chronic diseases, and a new paradigm for personalized medicine, one based on the patterns that can be gleaned from enormous volumes of individualized patient data, rather than on blood-based biomarkers.
Medical Device Platform Technologies

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009

Highlights from the Q1 2009 review of medical device and in vitro diagnostics/research dealmaking. Device financing activity remained down bringing in only $522 million--the majority invested through VCs, mostly via late-stage venture rounds--not much change from the previous quarter, but a significant drop from Q1 2008, which saw $920 million. Device M&A brought in $4.4 billion, double the previous quarter, but most of Q1's money came from Abbott's $2.86 billion purchase of Advanced Medical Optics. Four other transactions topped the $200 million mark, including three deals by device giant Medtronic, which grabbed cardio companies CoreValve, Ventor Technologies, and Ablation Frontiers. There was also a decline in in vitro diagnostics and research fund-raising with 2009's opening quarter only seeing about half the dollars of Q4 2008.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Biosite Diagnostics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Contact Info
  • Biosite Inc.
    Phone: (858) 805-8378
    9975 Summers Ridge Rd.
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register